Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Bio-Rad Laboratories A / Equity Bottom-Up

<ul><li>Bio-Rad Laboratories’ second-quarter 2026 financial results showed a broadly stable performance, with total revenue of approximately $651 million, essentially flat year-over-year on a reported basis and down 1.9% on a currency-neutral basis.</li><li>Sequentially, revenue improved 10%, driven by better execution across segments despite ongoing headwinds in certain end markets.</li><li>The Clinical Diagnostics segment returned to modest currency-neutral growth, led by quality controls and blood typing products.</li></ul>

Bio-Rad Laboratories’ second-quarter 2026 financial results showed a broadly stable performance, with total revenue of approximately $651 million, essentially flat year-over-year on a reported basis and down 1.9% on a currency-neutral basis.Sequentially, revenue improved 10%, driven by better execution across segments despite ongoing headwinds in certain end markets.The Clinical Diagnostics segment returned to modest currency-neutral growth, led by quality controls and blood typing products.

Bio-Rad’s Elliott Management Catalyst — Can It Close The Valuation Gap?

<ul><li>Bio-Rad Laboratories has suddenly become one of the most interesting activist stories in healthcare.</li><li>Elliott Investment Management has reportedly built a sizable stake in the life-science tools and diagnostics company after a brutal stock-market decline that erased more than 70% of Bio-Rad’s value from its pandemic-era peak.</li><li>The setup is easy to understand: a once-prized healthcare supplier is now trading far below its former highs, its margins are under pressure, and its investment in Sartorius is worth billions.</li></ul>

Bio-Rad Laboratories has suddenly become one of the most interesting activist stories in healthcare.Elliott Investment Management has reportedly built a sizable stake in the life-science tools and diagnostics company after a brutal stock-market decline that erased more than 70% of Bio-Rad’s value from its pandemic-era peak.The setup is easy to understand: a once-prized healthcare supplier is now trading far below its former highs, its margins are under pressure, and its investment in Sartorius is worth billions.

Elliott Is Circling Bio-Rad: Can This Fallen Healthcare Giant Wake Up?

<ul><li>Bio-Rad Laboratories reported modest growth in net sales for the first quarter of 2026, with revenues reaching approximately $592 million, a 1.1% increase on a reported basis compared to the prior year’s quarter.</li><li>However, on a currency-neutral basis, revenues declined by 4.2%, reflecting ongoing challenges in key markets.</li><li>The company’s Life Science segment experienced flat reported sales at $229 million, but a 4.3% decrease on a currency-neutral basis, mainly due to constrained academic research demand, particularly in the Americas, and softness in biopharma consumables.</li></ul>

Bio-Rad Laboratories reported modest growth in net sales for the first quarter of 2026, with revenues reaching approximately $592 million, a 1.1% increase on a reported basis compared to the prior year’s quarter.However, on a currency-neutral basis, revenues declined by 4.2%, reflecting ongoing challenges in key markets.The company’s Life Science segment experienced flat reported sales at $229 million, but a 4.3% decrease on a currency-neutral basis, mainly due to constrained academic research demand, particularly in the Americas, and softness in biopharma consumables.

Bio-Rad Laboratories: Inside The QX700 Push Driving A High-Impact Diagnostic Platform Strategy!

<ul><li>Bio-Rad Laboratories reported a moderate financial performance for the fiscal year 2025, reflecting both achievements and challenges.</li><li>The company’s revenue for the fourth quarter stood at approximately $693 million, marking a 3.9% increase from the previous year.</li><li>For the full year, net sales rose to $2.583 billion, a slight rise of 0.7% from the previous year.</li></ul>

Bio-Rad Laboratories reported a moderate financial performance for the fiscal year 2025, reflecting both achievements and challenges.The company’s revenue for the fourth quarter stood at approximately $693 million, marking a 3.9% increase from the previous year.For the full year, net sales rose to $2.583 billion, a slight rise of 0.7% from the previous year.

Inside Bio-Rad’s Digital PCR Bet — Why QX700 Could Redefine Its Long-Term Growth Trajectory!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

United States

Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products, clinical diagnostics, and analytical instrumentation.  The Company's products and systems separate complex chemical and biological materials, as well as identify, analyze, and purify their components.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bio-Rad Laboratories A (BIO US)

Bio-Rad’s Elliott Management Catalyst — Can It Close The Valuation Gap?

Bio-Rad Laboratories’ second-quarter 2026 financial results showed a broadly stable performance, with total revenue of approximately $651 million,...

Baptista Research

Elliott Is Circling Bio-Rad: Can This Fallen Healthcare Giant Wake Up?

Bio-Rad Laboratories has suddenly become one of the most interesting activist stories in healthcare. Elliott Investment Management has reportedly...

Baptista Research

Bio-Rad Laboratories: Inside The QX700 Push Driving A High-Impact Diagnostic Platform Strategy!

Bio-Rad Laboratories reported modest growth in net sales for the first quarter of 2026, with revenues reaching approximately $592 million, a 1.1%...

Baptista Research

Inside Bio-Rad’s Digital PCR Bet — Why QX700 Could Redefine Its Long-Term Growth Trajectory!

Bio-Rad Laboratories reported a moderate financial performance for the fiscal year 2025, reflecting both achievements and challenges. The...

Baptista Research

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)